VIP

VIP peptides · P01282 · VIP on Sugi Atlas →

51 patent compounds predicted against VIP, 32 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sceptrin (SCHEMBL31027459)	0.98	2/20
Sceptrin (SCHEMBL31027460)	0.98	2/20
SCHEMBL31027455	0.59	2/20
SCHEMBL31027458	0.59	2/20
Bromoageliferin (SCHEMBL14985474)	0.59	2/20
SCHEMBL13036733	0.57	2/20
SCHEMBL21182348	0.57	2/20
SCHEMBL12559790	0.54	2/20
SCHEMBL12597859	0.54	2/20
SCHEMBL12852200	0.54	2/20
Hydrochloric Acid (SCHEMBL30045379)	0.51	2/20
Keramadine (SCHEMBL11123414)	0.46	2/20
Keramadine (SCHEMBL11123417)	0.46	2/20
Hydrochloric Acid (SCHEMBL30092235)	0.65	1/20
SCHEMBL23952430	0.49	1/20
SCHEMBL13036735	0.47	1/20
SCHEMBL7845382	0.46	1/20
SCHEMBL28746425	0.46	1/20
SCHEMBL7843475	0.43	1/20
SCHEMBL15228546	0.43	1/20

Clinical trials — most relevant to VIP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients	PHASE4	COMPLETED
Vascular Effects of Sitagliptin in Diabetes Mellitus	PHASE4	UNKNOWN
AN-PEP on Gluten Exposure in Celiacs	PHASE4	COMPLETED
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19	PHASE3	WITHDRAWN
Liraglutide in Adolescents With Type 1 Diabetes	PHASE3	COMPLETED
Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.	PHASE3	COMPLETED
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus	PHASE3	COMPLETED
Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion in Patients With Type 2 Diabetes	PHASE3	UNKNOWN
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis	PHASE3	COMPLETED
Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus	PHASE3	COMPLETED
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure	PHASE2	COMPLETED
The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man	PHASE1	UNKNOWN
Plastic Bronchitis and Protein Losing Enteropathy in Children With Single Ventricle Physiology	nan	COMPLETED
The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by Magnetic Resonance Angiography (MRA) on Healthy Volunteers	nan	COMPLETED
The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients	nan	COMPLETED
The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) on Headache, Cranial Hemodynamic and Autonomic Symptoms in Healthy Volunteers	nan	COMPLETED
NDPH Biomarker Study in Children and Adolescents	nan	COMPLETED
Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache	nan	COMPLETED
Functional Lipids and Appetite Regulation	nan	COMPLETED
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	nan	RECRUITING
Moderate Continuous Versus High Interval Intensity Training on Gut Dysbiosis and GLP1 Hormone in IBS	nan	COMPLETED
The Endocrine Colon in Humans	nan	UNKNOWN
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Effects of Green Banana BIOmass Consumption in Patients With Pre-diabetes and Diabetes MELlitus (The BIOMEL Study)	nan	UNKNOWN
Plasma Determination of Glucagon-like Peptide 2 as a Predictor of Recovery in Adults With Acute Intestinal Failure	nan	COMPLETED
Predicting Relapse of Ulcerative Colitis With Gastrointestinal Ultrasound	nan	UNKNOWN
Magnetic Resonance Imaging of Motility in Crohn's 2	nan	COMPLETED
Relative Contribution of Brain Insulin Action for Postprandial Metabolism	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a VIP binder may also engage these)

Protein	Name	Similarity
P81401	—	1.000	P81401 →
P32648	—	1.000	P32648 →
P01283	—	1.000	P01283 →
P13589	—	0.994	P13589 →
Q91189	—	0.993	Q91189 →
Q9PUR0	—	0.992	Q9PUR0 →
P06883	—	0.991	P06883 →
P41585	—	0.989	P41585 →
O12956	—	0.989	O12956 →
Q9PUR1	—	0.989	Q9PUR1 →
Q29W19	—	0.989	Q29W19 →
P56943	—	0.989	P56943 →
P28672	—	0.989	P28672 →
P01304	—	0.988	P01304 →
O35417	—	0.988	O35417 →
P28673	—	0.988	P28673 →
P04204	—	0.987	P04204 →
P07808	—	0.987	P07808 →
P40147	—	0.987	P40147 →
E7EZ53	—	0.987	E7EZ53 →
P04092	—	0.987	P04092 →
P69156	—	0.987	P69156 →
P79695	—	0.987	P79695 →
P01273	—	0.987	P01273 →
P01303	—	0.987	P01303 →
Q9D3P9	—	0.987	Q9D3P9 →
P19713	—	0.987	P19713 →
P49794	—	0.987	P49794 →
P68259	—	0.987	P68259 →
O70176	—	0.987	O70176 →